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Conclusions: TG119 structures and plans were found to be easily 
adaptable to Delta4 phantom CT enabling a rigorous evaluation 
procedure for IMRT plans verification. Preliminary results on VMAT 
plans showed that TG119 could be a practical commissioning 
procedure for modulated arc therapy too. Delta4 allows a fast on-line 
3D dose distributions analysis substituting more traditional dosimeters 
suggested in TG119, but this solution is more expensive than the one 
proposed inside this report and it is not available in every department 
for intercomparison purposes. 
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Purpose/Objective: Quality control (QC) of volumetric modulated arc 
therapy (VMAT) delivery represents a significant additional workload 
during monthly accelerator checks. This study therefore aims to 
implement VMAT QC in as few arcs as possible using portal imaging. 
Synchronisation between gantry position, multileaf collimator (MLC) 
leaves and dose rate is the focus of the study, since this is the aspect 
which is covered least by already-implemented tests of intensity 
modulated radiation therapy (IMRT) delivery. 
Materials and Methods: An Agility accelerator with iViewGT portal 
imager (Elekta AB, Stockholm, Sweden) was used for this study. A 
steel bar of diameter 12 mm was accurately positioned in the G-T 
direction, 80 mm laterally from the isocentre (Figure 1a). An arc 
prescription was designed which irradiated the bar with a 16 mm x 
220 mm field during a complete 360° arc, so as to cast a shadow of 
the bar onto the portal imager. This resulted in a sinusoidal sweep of 
the field and shadow across the portal imager and back. The 
prescribed monitor units (MU) were chosen so as to give a uniform 
intensity during this sweep. A total of 640 MU were delivered with 
control point spacing 10°. The method was tested by simulating an 
MLC leaf position error of 2 mm at one control point, a gantry position 
error of 9° at one control point, and a dose error of 20 MU (3% of 
overall dose) at one control point. The portal images were viewed as 
integrated images. Coefficient of variation of mid-leaf profiles was 
used to evaluate the magnitude of features appearing in the portal 
images due to simulated errors. 
Results: The test requires a counter-clockwise arc and a clockwise arc 
to fully evaluate the VMAT performance of all MLC leaves. In the 
absence of simulated errors, the integrated images show uniformity. 
With simulated delivery errors, irregular patterns appear in the 
integrated portal images (Figures 1b - 1d). The increase in coefficient 
of variation relative to no delivery error is 42% due to a 2 mm MLC 
leaf position error at one control point, 108% due to a 9° gantry 
position error at one control point and 239% due to a 20 MU dose error 
at one control point. The method is more sensitive to errors at gantry 
angle 90°/270° than at 0°/180° due to the geometry of the test. 
Conclusions: This method provides fast and effective VMAT QC 
suitable for inclusion in a monthly accelerator QC programme. The 
test is able to detect errors in the delivery of individual control 
points, with the possibility of using movie images to further 
investigate suspicious image features. We are grateful for engineering 
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Purpose/Objective: The predictive role of FDG-PET in identifying lung 
cancer patients at risk of relapse has opened for PET-guided 
simultaneous integrated boost (SIB), where the PET-active tumor 
region may be dose escalated [1]. Such treatment involves intensity 
modulated radiotherapy (IMRT), with a high degree of beam 
modulation, of a target positioned in the lungs. Dose calculation 
algorithms may show deficiencies under such conditions, and it is thus 
pivotal to verify whether the planned dose is correctly delivered. 
Materials and Methods: An anthropomorphic thorax phantom made of 
polystyrene (ρ=1.06,soft tissue surrogate) and polyurethane 
(ρ=0.25,lung tissue surrogate) was constructed in-house based on CT 
images of a lung cancer patient. One-hundred and one cylindrical 
cavities for alanine/EPRdosimeters (height 2.5 mm, diameter 5 mm) 
were made throughout the phantom. A SIB based on PET/CT images of 
the given patient was planned for a Varian Trilogy linear accelerator 
equipped with a 120 leaf Millennium multileaf collimator (Varian 
Medical Systems) using 6 MV photons. The IMRT boost plan objectives 
comprised, among others, a boost dose of 3.8 Gy/fraction to the FDG-
avid region including margins (biological planning volume; BTV) with 
3.1 Gy/fraction to the planning target volume (PTV, excluding the 
BTV). The IMRT plan was transferred to the anthropomorphic phantom 
where the dose distribution was calculated using the AAA algorithm in 
the Eclipse treatment planning system. Irradiation of the phantom, 
including 101 alanine/EPR dosimeters, was carried out at the linear 
accelerator in question. Phantom setup was verified with the 
accompanying OBI cone beam CT system, and portal dosimetry was 
performed for beam verification. A dosimeter calibration series with 
15 dosimeters was irradiated at the same accelerator. Readout of the 
alanine/EPR dosimeters were performed at an EleXsyS 560 Super X 
EPR spectrometer. 
Results: The phantom dose points were separated into four region 
categories; BTV, PTV (excluding BTV),lung tissue and nonspecific soft 
tissue. The mean measured versus calculated point doses within these 
regions were 3.83 vs3.84 Gy, 3.30 vs 3.29 Gy, 1.68 vs 1.63 Gy and 0.36 
vs 0.33 Gy, respectively. The mean relative difference in point doses 
(± 1 S.D.) between measurement and plan were (-0.5±1.8) %, 
(0.4±2.9) %,(5±13) % and (14±36) %, respectively. A high linear 
correlation between measured and planned doses (range 0.71-0.99) 
was seen in all regions. 
Conclusions: The PET-guided SIB can be delivered to patients with 
high dosimetric accuracy with the given planning and delivery system. 
Although some discrepancies are observed between measurements 
and calculations, these are mostly seen in non-specific soft tissue 
receiving very low doses and are most likely not clinically relevant. 
[1] van Elmpt, W., De Ruysscher, D., van der Salma,A., et al. The PET-
boost randomised phase II dose-escalation trial in non-small cell lung 
cancer. Radiother Oncol 2012; 104: 67-71. 
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Purpose/Objective: The aim of this work was to extend an EPID-based 
in-vivo dosimetry (IVD) method, developed in the last years by the 
authors for conformal radiotherapy, to step-and-shoot IMRT 
treatments of pelvic tumours. The algorithm was developed for Elekta 
linacs equipped with IviewGT EPIDs, with the aim to simplify the 
commissiong procedures and supply IVD tests in quasi-real time. 
Materials and Methods: The algorithm is based on correlation 
functions to convert EPID transit signals into in-vivo dose values, Diso, 
at the isocenter point. The EPID images were obtained by the so-
called 'IMRT Dosimetric Weighting' mode as a superposition of many 
segment fields. Each integral dosimetric image could be acquired in 
about 10 s after the end of beam delivery and could be processed 
while delivering the successive IMRT beams. A specific algorithm for 
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Diso reconstruction especially featured for step-and-shoot IMRT was 
implemented using a set of simulated IMRT beams. These beams were 
parameterized by means of a fluence inhomogeneity index, FI, 
introduced to describe the degree of beam modulation as respect to 
open beams. All the dosimetric parameters involved in the Diso 
reconstruction algorithm, such as the correlation functions, the 
correction factor for scattered contribution due to different EPID to 
phantom distances and the modulated tissue maximum ratios were 
measured taking into account the FI index. 20 clinical IMRT beams 
were tested and used to irradiate a homogeneous phantom; 100 IVD 
were reconstructed in 5 different geometrical set-up. In addition, the 
dedicated software supplied for each beam the γ-analysis of the 2D 
comparison between portal images to test the beam irradiation 
reproducibility. 
Results: 55 simulated IMRT beams, with FI index ranging from 0.5 to 
6, were used to generalize the IVD algorithm to step-and-shoot IMRT. 
Each of the 100 clinical tests (5 tests per beam) showed an agreement 
between the in-vivo dose, Diso, and the TPS dose, Diso,TPS, within 
5%. The agreement was better than 4% when the comparison was 
carried out between the averaged isocenter doses from all beams of 
each treatment. For all beams, the γ-analysis between subsequent 
portal images was within the tolerance levels (3%/3mm), supplying a 
γmean < 0.3 and a pass-rate Pγ<1 >96%. The results are supplied in 
quasi real-time: after only 2 minutes from the end overall plan 
delivery the IVD test for all beams are performed and displayed. 
Conclusions: The IVD procedure here presented is one of the goals of 
an Italian Project supported by the Istituto Nazionale di Fisica 
Nucleare (INFN). The results of this study confirm that it’s possible (i) 
to reach the accuracy of 5% for the IVD Diso test also for IMRT 
treatments and (ii) to obtain the IVD results in a quasi real time at the 
end of the treatment delivery. In addition, we remark that our IVD 
procedure needs an easy commissioning for all Elekta linacs equipped 
with IviewGT aSi-EPID.  
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Purpose/Objective: In small fields dosimetry the measurement of 
output factors (OF) is affected by detectors effects, as the volume 
averaging effect for ionization chambers or higher scatter due to the 
presence of high Z material for diodes; the use of correction factors to 
the experimental measurements is therefore necessary for accurate 
results. For the Cyberknife system the correcting factors from Monte 
Carlo simulations, for several active dosimeters, have been recently 
published. The radiochromic films, characterized by high spatial 
resolution and water equivalence, could be considered an 'effects free 
detector', thus a valid alternative approach. Aim of this work is the 
measurement of OF with radiochromic films for small fields on a 
Cyberknife unit. 
Materials and Methods: EBT3 radiochromic films (batch #A04031201) 
were used to measure the output factor (OF), hereinafter referred to 
as OFgaf, in solid water at 15mm depth, at 800mm reference source-
to-distance detector (SDD) on a Cyberknife® system (6MV, 800mu min-
1) for fixed collimators with diameters ranging from 5mm to 25mm. 
During the system's commissioning the OF were measured at same 
depth and SDD in water phantom with a stereotactic diode (PTW 
model 60017), hereinafter referred to as OFdiode. For each fixed 
collimator 3 precut films were irradiated at a nominal dose of 400cGy: 
the necessary MU to obtain a nominal dose of 400cGy were calculating 
starting from the OFdiode. After 24 hours from the irradiation the films 
were acquired with a flatbed scanner (Epson V750pro) in transmission 
mode, 48 bit color, 150 dpi resolution. A dose calibration curve was 
obtained for the same batch. The green channel response were 
considered. For each field the OFgaf is calculated as the ratio between 
the measured dose per MU normalized to the measured dose per MU of 
the 60mm collimator. The mean dose was evaluated with two circular 
ROIs with diameter equal to 0.5mm (ROIA) and of 1.2mm (ROIB), 
centered on the field's centroid. The field's centroid were estimated 
with an automatic growing tools on the thresholded image. The 
analysis of the films were performed in ImageJ® with an automatic 
plugin. The results from both ROIs were compared to OFdiode. 
Results: With ROIA the percentage difference between the OFgaf and 
OFdiode ranges from -4.5% to -1.7%, with ROIB the percentage 
difference ranges from -5.4% to -1.4% for collimator from 5mm to 
12.5mm; for the other collimators the differences are negligible. 
Applying the Monte Carlo correction factors to the commissioning data 
the difference for the smallest collimator decrease to -0.1% and -1.1% 
for ROIA and ROIB respectively. 
Conclusions: The radiochromic films results have shown good 
agreement with the commissioning data, once the Monte Carlo 
correction have been applied. Moreover the results agree with the 
diodes' data for collimators larger than 12.5mm, for which the Monte 
Carlo corrections are negligible. The use of radiochromic films for 
estimating the output factors could be suggested as a valid 
comparison method for a Cyberknife® system.  
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Purpose/Objective: To demonstrate that precise skin dose 
measurement is possible with EBT2 films. 
Materials and Methods: A post-mastectomy breast cancer patient was 
followed with in vivo dosimetry during the full course of radiation 
treatment. Treatment consisted of 50Gy/25fx to the whole chestwall 
and supraclavicular region, followed with a boost of 10Gy/5fx to the 
surgery scar. The patient was treated on the TomoTherapy Hi-Art II 
system using a 4-field TomoDirect treatment for the chestwall and a 
TomoHelical treatment for the boost. The boost was planned and 
treated with a 0.5cm bolus covering the mastectomy scar. Gafchromic 
EBT2 films were cut to square pieces of ~1-2mm. A 5-film sample was 
placed at each of the medial and lateral scar extremities. The film 
pieces were affixed to the patient’s skin using surgical tape. Film 




Results: One measurement from the chestwall treatment was not 
included in analysis due to scanner error. For the chestwall 
treatment, the medial mean dose measured 106.9cGy (σ=3.7cGy) 
while the lateral mean dose measured 127.6cGy (σ=5.5cGy). For the 
boost treatment, the medial mean dose measured 197.9cGy 
(σ=6.4cGy) while the lateral mean dose measured 187.8cGy 
(σ=5.9cGy). The STDs in measured dose observed for the boost 
treatment positions are decreased to 1.7cGy and 3.1cGy respectively 
with the exclusion of one fraction from the data set.  
Conclusions: Intrinsic error due to the film and dosimetry method is 
estimated at 1.4cGy, therefore points outside of ±3σ (4.2cGy) are 
significant.1 Though, uncertainty in film placement on the patient is 
included in the measurements and must be taken into account when 
scrutinizing these results. The STD in dose measurements was 
noticeably larger for the lateral position compared to the medial 
position. This result is hypothesized to be due to variability in 
ipsilateral axillar repositioning we’ve observed in breast patients. 
Accuracy of the film measurements with respect to the TPS 
calculation was not a goal of the study. The depth of measurement of 
EBT2 films is approx. 0.1mm and therefore skin dose measurement 
comparison to calculation is premature due to voxel size dose 
averaging and TPS calculation uncertainties in the buildup region. Yet, 
all boost measurements, with exemption to one fraction, showed very 
good agreement with the calculation. This result can be explained 
because of the use of a 0.5cm bolus in the boost plan and the skin’s 
inclusion within the PTV, thereby avoiding the voxel averaging and 
TPS uncertainties observed in the buildup region. The outlying boost 
result could be due to an error in the film’s placement. A 4mm 
displacement, i.e. 2-pixel shift in calculation, on the skin correlates 
with a decrease of 20cGy in calculated dose due to the high gradient 
in the boost plan.  
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